Skip to main content
Erschienen in: Medical Oncology 2/2016

01.02.2016 | Original Paper

27-Hydroxycholesterol stimulates cell proliferation and resistance to docetaxel-induced apoptosis in prostate epithelial cells

verfasst von: Shaneabbas Raza, Megan Meyer, Jared Schommer, Kimberly D. P. Hammer, Bin Guo, Othman Ghribi

Erschienen in: Medical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Although the causes of prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are not known, the role of oxidative stress, aging, and diet are suspected to increase the incidence of prostate complications. The cholesterol oxidation derivative (oxysterol) 27-hydroxycholesterol (27-OHC) is the most prevalent cholesterol metabolite in the blood. As aging, oxidative stress, and hypercholesterolemia are associated with increased risk of PCa and BPH, and because 27-OHC levels are also increased with aging, hypercholesterolemia, and oxidative stress, determining the role of 27-OHC in the progression of PCas and BPH is warranted. In this study, we determined the effect of 27-OHC in human prostate epithelial cells RWPE-1. We found that 27-OHC stimulates proliferation and increases androgen receptor (AR) transcriptional activity. 27-OHC also increased prostate-specific antigen expression and enhanced AR binding to the androgen response element compared to controls. Silencing AR expression with siRNA markedly reduced the 27-OHC-induced proliferation. Furthermore, 27-OHC blocked docetaxel-induced apoptosis. Altogether, our results suggest that 27-OHC may play an important role in PCa and BPH progression by promoting proliferation and suppressing apoptosis.
Literatur
1.
Zurück zum Zitat Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17:241–6.CrossRefPubMed Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17:241–6.CrossRefPubMed
2.
Zurück zum Zitat Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006;13:158–68.PubMed Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006;13:158–68.PubMed
3.
Zurück zum Zitat Chokkalingam AP, Nyrén O, Johansson J-E, Gridley G, McLaughlin JK, Adami H-O, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer. 2003;98:1727–34.CrossRefPubMed Chokkalingam AP, Nyrén O, Johansson J-E, Gridley G, McLaughlin JK, Adami H-O, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer. 2003;98:1727–34.CrossRefPubMed
4.
Zurück zum Zitat Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2013;10:49–54.CrossRefPubMed Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2013;10:49–54.CrossRefPubMed
5.
Zurück zum Zitat White CP. On the occurrence of crystals in tumours. J Pathol Bacteriol. 1909;13:3–10.CrossRef White CP. On the occurrence of crystals in tumours. J Pathol Bacteriol. 1909;13:3–10.CrossRef
6.
Zurück zum Zitat Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010;21:61–8.PubMedCentralCrossRefPubMed Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010;21:61–8.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Breau RH, Karnes RJ, Jacobson DJ, McGree ME, Jacobsen SJ, Nehra A, et al. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol. 2010;184:494–9.PubMedCentralCrossRefPubMed Breau RH, Karnes RJ, Jacobson DJ, McGree ME, Jacobsen SJ, Nehra A, et al. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol. 2010;184:494–9.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer. 2011;47:819–30.CrossRefPubMed Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer. 2011;47:819–30.CrossRefPubMed
9.
Zurück zum Zitat Lee SH, Park TJ, Bae MH, Choi SH, Cho YS, Joo KJ, et al. Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia. Korean J Urol. 2013;54:750–5.PubMedCentralCrossRefPubMed Lee SH, Park TJ, Bae MH, Choi SH, Cho YS, Joo KJ, et al. Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia. Korean J Urol. 2013;54:750–5.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342:1094–8.PubMedCentralCrossRefPubMed Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342:1094–8.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Hirayama T, Mizokami Y, Honda A, Homma Y, Ikegami T, Saito Y, et al. Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level. Hepatol Res. 2009;39:149–56.CrossRefPubMed Hirayama T, Mizokami Y, Honda A, Homma Y, Ikegami T, Saito Y, et al. Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level. Hepatol Res. 2009;39:149–56.CrossRefPubMed
13.
Zurück zum Zitat DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP. 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. 2008;22:65–77.PubMedCentralCrossRefPubMed DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP. 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. 2008;22:65–77.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, et al. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001;276:38378–87.CrossRefPubMed Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, et al. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001;276:38378–87.CrossRefPubMed
15.
Zurück zum Zitat Cruz P, Torres C, Ramírez ME, Epuñán MJ, Valladares LE, Sierralta WD. Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol. Exp Ther Med. 2010;1:531–6.PubMedCentralPubMed Cruz P, Torres C, Ramírez ME, Epuñán MJ, Valladares LE, Sierralta WD. Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol. Exp Ther Med. 2010;1:531–6.PubMedCentralPubMed
16.
Zurück zum Zitat Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 2013;5:637–45.PubMedCentralCrossRefPubMed Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 2013;5:637–45.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Horie-Inoue K, Bono H, Okazaki Y, Inoue S. Identification and functional analysis of consensus androgen response elements in human prostate cancer cells. Biochem Biophys Res Commun. 2004;325:1312–7.CrossRefPubMed Horie-Inoue K, Bono H, Okazaki Y, Inoue S. Identification and functional analysis of consensus androgen response elements in human prostate cancer cells. Biochem Biophys Res Commun. 2004;325:1312–7.CrossRefPubMed
18.
Zurück zum Zitat Nelson ER, DuSell CD, Wang X, Howe MK, Evans G, Michalek RD, et al. The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors. Endocrinology. 2011;152:4691–705.PubMedCentralCrossRefPubMed Nelson ER, DuSell CD, Wang X, Howe MK, Evans G, Michalek RD, et al. The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors. Endocrinology. 2011;152:4691–705.PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Ma D, Liu W, Wang Y. ApoA-I or ABCA1 expression suppresses fatty acid synthesis by reducing 27-hydroxycholesterol levels. Biochimie. 2014;103:101–8.CrossRefPubMed Ma D, Liu W, Wang Y. ApoA-I or ABCA1 expression suppresses fatty acid synthesis by reducing 27-hydroxycholesterol levels. Biochimie. 2014;103:101–8.CrossRefPubMed
20.
Zurück zum Zitat Burkard I, von Eckardstein A, Waeber G, Vollenweider P, Rentsch KM. Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis. 2007;194:71–8.CrossRefPubMed Burkard I, von Eckardstein A, Waeber G, Vollenweider P, Rentsch KM. Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis. 2007;194:71–8.CrossRefPubMed
21.
Zurück zum Zitat Dzeletovic S, Breuer O, Lund E, Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem. 1995;225:73–80.CrossRefPubMed Dzeletovic S, Breuer O, Lund E, Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem. 1995;225:73–80.CrossRefPubMed
22.
Zurück zum Zitat Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007;13:1185–92.CrossRefPubMed Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007;13:1185–92.CrossRefPubMed
23.
Zurück zum Zitat DuSell CD, Nelson ER, Wang X, Abdo J, Mödder UI, Umetani M, et al. The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology. 2010;151:3675–85.PubMedCentralCrossRefPubMed DuSell CD, Nelson ER, Wang X, Abdo J, Mödder UI, Umetani M, et al. The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology. 2010;151:3675–85.PubMedCentralCrossRefPubMed
24.
Zurück zum Zitat Marwarha G, Ghribi O. Does the oxysterol 27-hydroxycholesterol underlie Alzheimer’s disease-Parkinson’s disease overlap? Exp Gerontol. 2015;68:13–8.CrossRefPubMed Marwarha G, Ghribi O. Does the oxysterol 27-hydroxycholesterol underlie Alzheimer’s disease-Parkinson’s disease overlap? Exp Gerontol. 2015;68:13–8.CrossRefPubMed
25.
26.
Zurück zum Zitat Schüle R, Siddique T, Deng H-X, Yang Y, Donkervoort S, Hansson M, et al. Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis. J Lipid Res. 2010;51:819–23.PubMedCentralCrossRefPubMed Schüle R, Siddique T, Deng H-X, Yang Y, Donkervoort S, Hansson M, et al. Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis. J Lipid Res. 2010;51:819–23.PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Meaney S, Lütjohann D, Diczfalusy U, Björkhem I. Formation of oxysterols from different pools of cholesterol as studied by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice. Biochim Biophys Acta. 2000;1486:293–8.CrossRefPubMed Meaney S, Lütjohann D, Diczfalusy U, Björkhem I. Formation of oxysterols from different pools of cholesterol as studied by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice. Biochim Biophys Acta. 2000;1486:293–8.CrossRefPubMed
28.
Zurück zum Zitat Meaney S, Hassan M, Sakinis A, Lütjohann D, von Bergmann K, Wennmalm A, et al. Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. J Lipid Res. 2001;42:70–8.PubMed Meaney S, Hassan M, Sakinis A, Lütjohann D, von Bergmann K, Wennmalm A, et al. Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. J Lipid Res. 2001;42:70–8.PubMed
29.
Zurück zum Zitat Ramirez DMO, Andersson S, Russell DW. Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J Comp Neurol. 2008;507:1676–93.PubMedCentralCrossRefPubMed Ramirez DMO, Andersson S, Russell DW. Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J Comp Neurol. 2008;507:1676–93.PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Bandaru VVR, Haughey NJ. Quantitative detection of free 24S-hydroxycholesterol, and 27-hydroxycholesterol from human serum. BMC Neurosci. 2014;15:137.PubMedCentralCrossRefPubMed Bandaru VVR, Haughey NJ. Quantitative detection of free 24S-hydroxycholesterol, and 27-hydroxycholesterol from human serum. BMC Neurosci. 2014;15:137.PubMedCentralCrossRefPubMed
31.
Zurück zum Zitat Cruz P, Epuñán MJ, Ramírez ME, Torres CG, Valladares LE, Sierralta WD. 27-hydroxycholesterol and the expression of three estrogen-sensitive proteins in MCF7 cells. Oncol Rep. 2012;28:992–8.PubMed Cruz P, Epuñán MJ, Ramírez ME, Torres CG, Valladares LE, Sierralta WD. 27-hydroxycholesterol and the expression of three estrogen-sensitive proteins in MCF7 cells. Oncol Rep. 2012;28:992–8.PubMed
32.
34.
Zurück zum Zitat Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009;10:981–91.PubMedCentralCrossRefPubMed Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009;10:981–91.PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Lu T, Lin W-J, Izumi K, Wang X, Xu D, Fang L-Y, et al. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol. 2012;26:1707–15.PubMedCentralCrossRefPubMed Lu T, Lin W-J, Izumi K, Wang X, Xu D, Fang L-Y, et al. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol. 2012;26:1707–15.PubMedCentralCrossRefPubMed
36.
Zurück zum Zitat Izumi K, Mizokami A, Lin W-J, Lai K-P, Chang C. Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 2013;182:1942–9.PubMedCentralCrossRefPubMed Izumi K, Mizokami A, Lin W-J, Lai K-P, Chang C. Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 2013;182:1942–9.PubMedCentralCrossRefPubMed
37.
Zurück zum Zitat Saxena P, Trerotola M, Wang T, Li J, Sayeed A, Vanoudenhove J, et al. PSA regulates androgen receptor expression in prostate cancer cells. Prostate. 2012;72:769–76.PubMedCentralCrossRefPubMed Saxena P, Trerotola M, Wang T, Li J, Sayeed A, Vanoudenhove J, et al. PSA regulates androgen receptor expression in prostate cancer cells. Prostate. 2012;72:769–76.PubMedCentralCrossRefPubMed
38.
Zurück zum Zitat Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004;93:233–41.CrossRefPubMed Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004;93:233–41.CrossRefPubMed
39.
Zurück zum Zitat Hipfner DR, Cohen SM. Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol. 2004;5:805–15.CrossRefPubMed Hipfner DR, Cohen SM. Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol. 2004;5:805–15.CrossRefPubMed
40.
Zurück zum Zitat Mhaidat NM, Thorne RF, Zhang XD, Hersey P. Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Mol Cancer Res. 2007;5:1073–81.CrossRefPubMed Mhaidat NM, Thorne RF, Zhang XD, Hersey P. Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Mol Cancer Res. 2007;5:1073–81.CrossRefPubMed
41.
Zurück zum Zitat Petrylak DP. The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol. 2006;8(Suppl 2):S48–55.PubMedCentralPubMed Petrylak DP. The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol. 2006;8(Suppl 2):S48–55.PubMedCentralPubMed
42.
Zurück zum Zitat Kellokumpu-Lehtinen P-L, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14:117–24.CrossRefPubMed Kellokumpu-Lehtinen P-L, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14:117–24.CrossRefPubMed
43.
Zurück zum Zitat McKeage K, Keam SJ. Docetaxel in hormone-refractory metastatic prostate cancer. Drugs. 2005;65:2287–94 (discussion 2295–7).CrossRefPubMed McKeage K, Keam SJ. Docetaxel in hormone-refractory metastatic prostate cancer. Drugs. 2005;65:2287–94 (discussion 2295–7).CrossRefPubMed
44.
Zurück zum Zitat Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, et al. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer. 2015;14:122.PubMedCentralCrossRefPubMed Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, et al. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer. 2015;14:122.PubMedCentralCrossRefPubMed
Metadaten
Titel
27-Hydroxycholesterol stimulates cell proliferation and resistance to docetaxel-induced apoptosis in prostate epithelial cells
verfasst von
Shaneabbas Raza
Megan Meyer
Jared Schommer
Kimberly D. P. Hammer
Bin Guo
Othman Ghribi
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0725-5

Weitere Artikel der Ausgabe 2/2016

Medical Oncology 2/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.